An interventional study of ALLEVYN Non-Adhesive in Wounds, Wound of Skin and Wound Leg, sponsored by Molnlycke Health Care AB. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by Molnlycke Health Care AB · Not applicable, Interventional, and Supportive care
The goal of this clinical trial to follow the progress of wounds in those with chronic venous leg ulcers while using a non-bordered foam dressing. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.
Participants will be asked to wear the dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.
This investigation is designed as a prospective, open, multi-center, interventional, non-comparative investigation with the aim to follow chronic wound progression for 6 weeks according to local standard of care. Wound progress is a summary endpoint of the total effect of treatment using the non-bordered foam dressing as the absorbent dressing and includes the changes in an objectively measured wound area and subjectively evaluated wound condition. The only included indication is Venous Leg Ulcers (VLU). A total of n=20 participants will be recruited at up to 6 centers within the US and Canada.
There will be a total of seven (7) visits to the investigation site for participants during the treatment period: baseline, followed by weekly visits up to six (6) weeks post baseline. During visits, evaluations will be performed to assess wound progression and status, wound dressing properties, as well as Subject pain, comfort, and quality of life. Safety will be assessed at all visits. One target wound per participant will be included in this investigation.
378 studies on the registry are indexed under Varicose Ulcer; 80 are open to participants now.
This study's planned enrollment of 20 is below the median of 64 across 325 interventional studies indexed under Varicose Ulcer.
Browse Varicose Ulcer studies →Molnlycke Health Care AB is the lead sponsor of 58 studies on the registry; 7 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All Subjects will use a non-bordered foam dressing as the absorbent primary dressing.
Device: ALLEVYN Non-Adhesive
ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction. ALLEVYN Non-Adhesive consists of the following layers: * Breathable top film * Highly absorbent foam core * Non-adhesive wound contact layer
Wound progress of the total effect of treatment using ALLEVYN Non-Adhesive
Wound progress is the total effect of treatment using ALLEVYN Non-Adhesive as the absorbent dressing and includes the changes in an objectively measured wound area and subjectively evaluated wound condition by the treating investigator/designee. Wound progress will be assessed as deteriorated, no change, improved, or healed at each visit. Wound area will be measured by an independent evaluator assisted by digital software at each visit and recorded as cm2 using the formula, A= π\*L\*W/4.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Percentage wound area reduction over time
The percentage of wound area (cm2) reduction over time will be assessed by a formula as the area of an ellipse and measured by an independent evaluator assisted by digital software on all digital photographs taken at each scheduled visit.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Linear wound healing over time
The linear wound healing will be calculated with Gilman's formula (cm/day), G = - (A1-A0)/ {\[(P1+P0)/2\]\*(t1-t0)}, where: A0 = previous visit area A1 = current visit area P0 = previous visit perimeter P1 = current visit perimeter t0 = previous visit time t1 = current visit time. Area (A) and Perimeter (P) will be assessed by an independent evaluator assisted by digital software. Perimeter (P) will be measured in cm and Area (A) will be assessed in cm2.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Change in granulation tissue over time
The area of wound covered by granulation tissue, (%) before and after cleansing/debridement will be assessed as follows: 1) via an independent evaluator assisted by digital software; and 2) via visual judgement by investigator/designee and determined as: None, 1%-24%, 25%-49%, 50%-74%, or 75%-100%.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Change in sloughy tissue over time
The area of wound covered by sloughy tissue, (%) before and after cleansing/debridement will be assessed as follows: 1) via an independent evaluator assisted by digital software; and 2) via visual judgement by investigator/designee and determined as: None, 1%-24%, 25%-49%, 50%-74%, or 75%-100%.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Change in exudate amount over time
Exudate amount will be captured as a subjective measure from the investigator/designee and assessed as none, scant, small, moderate, or large.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Change in exudate nature over time
Exudate nature will be captured as a subjective measure from the investigator/designee via the following category descriptive scale: serous, serosanguinous, sanguineous, seropurulent, fibrinous, purulent, hemopurulent, or hemorrhagic.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Change in peri-wound skin condition over time
The change in peri-wound skin condition over time will be assessed by visual assessment (No/Yes) by investigator/designee for maceration, dry skin, erythema/redness, and other peri-wound skin conditions.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Change in maceration over time
Area of wound covered by macerated tissue (%) will be assessed before debridement in cm2 by an independent evaluator assisted by digital software. The maximal distance (cm) from as close to the wound edge as possible to the end of maceration, assessed from wound photo, taken before debridement, by an independent evaluator assisted by digital software. The area of maceration will be assessed from a wound photo taken before debridement by an independent evaluator assisted by digital software.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Wound/Peri-Wound itch score prior to dressing removal over time (PRO)
The Subject itch severity before dressing removal over time will be assessed at all follow-up visits using the Numerical Rating Scale (NRS). The Subject verbally rates their level of itchiness on a level from 0 to 10, where 0 indicates no itch and 10 is the worst itch.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Wound pain score during dressing wear over time (PRO)
Subject pain severity during dressing wear over time will be assessed at all follow-up visits using the Numerical Rating Scale (NRS). The Subject verbally rates the pain on a level from 0 to 10, where 0 indicates no pain and 10 is the worst pain.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Wound pain score related to removal of dressing over time (PRO)
Subject pain severity at dressing removal will be assessed at all follow-up visits using the NRS scale where the Subject verbally rates the pain on a level from 0 to 10, where 0 indicates no pain and 10 is the worst pain. Any pre-procedural or intra-procedural pain medication administered at the time of dressing removal will be recorded.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Trauma to the wound/peri-wound during dressing removal over time
Trauma to the wound will be captured via visual judgement by the investigator/desginee using an ordinal scale of none, very slight, moderate, or high. Trauma to the peri-wound skin will be captured via visual judgement by the investigator/designee using the ordinal scale of none, very slight, moderate, or high.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Primary dressing's ability to be comfortable to wear (PRO)
Subjects will be asked to rate the dressing's degree of comfort using a 4-item scale of very poor, poor, good, or very good.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Dressing's ability to be comfortable to wear with compression (PRO)
Subjects will be asked to rate the dressing's degree of comfort while wearing with compression using a 4-item scale of very poor, poor, good, or very good.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Evaluation of Wound Quality of Life (QoL) (PRO)
A Wound-QoL-17 questionnaire will be completed by each Subject to measure the disease-specific, health-related QoL of those with chronic wounds. All items assess impairments within the preceding seven days.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Technical Performance (Investigator/designee's evaluation)
Several questions will be asked to evaluate the technical performance properties of the primary dressing. The following will be assessed by the investigator/designee using no/yes values: 1) Occurrence of strike-through, defined as the inability of the dressing to stay sealed over the wound causing leakage of wound exudate; and 2) Occurrence of product residue in the wound bed or on peri-wound skin after dressing removal. All other properties will be assessed by the investigator/designee using a 4-item scale of very poor, poor, good, very good. These include: * Ability to absorb exudates with different viscosities, * Ability to retain exudate, * Ease of application, * Ability to conform to the wound during wear, * Ability to be repositioned during application, * Inability to adhere to moist wound bed, * Ability to adhere to healthy, intact skin, * Ability to stay on during application and use, * Overall satisfaction with the dressing's properties.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Status of dressing during a routine dressing change or complication
The status of the primary dressing during a routine dressing change or complication will be assessed by the investigator/designee as strike-through, saturated, displaced/slipping, or other. This will be recorded in the Dressing Log.
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Pre-compression edema
The specification of any pre-compression edema prior to applying/changing compression therapy will be assessed by the investigator/designee as: * 0 (no clinical edema) * 1+ (≤2 mm indentation) * 2+ (2-4 mm indentation) * 3+ (4-6 mm indentation) * 4+ (6-8 mm indentation)
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Compression removed/changed/applied
Assessment of compression by the investigator/designee will cover: * Compression removal (No/Yes) * Compression changed/applied (No/Yes) * Type of compression used
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Compliance with compression
The investigator/designee will evaluate Subject compliance with compression. Assessment will include being fully compliant (defined as 7 out of 7 days with compression), moderately compliant (defined as 1 to 3 days without compression out of 7 days), or not compliant (defined as \>3 days without compression out of 7 days).
Time frame: A maximum total treatment period of 44 days or until healed, whichever occurs first.
Wear time (days)
Wear time will be determined from the Subject Dressing Log at each visit by collecting: * Date of dressing application/change * Reason for change application/change * Lot/batch * Size * Quantity
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Debridement performed
The following debridement details will be recorded for each Subject at each visit: * Debridement performed (No/Yes) * Debridement method * Ease of debridement (Very easy/Easy/Difficult/Very Difficult)
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Cleansing performed
The following cleansing details will be recorded for each Subject at each visit: * Cleansing performed (No/Yes) * Type of cleansing agent used
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Evaluation of all reported adverse events and device deficiencies
If any reported adverse events or device deficiencies are reported, an evaluation will take place to determine root cause.
Time frame: From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Molnlycke Health Care AB